Search
Herpes Simplex
go.drugbank.com/conditions/DBCOND0027882Drugs: LysozymeSynonyms: Herpes simplex complexValine
go.drugbank.com/drugs/DB00161ApprovedInvestigationalNutraceuticalIt is a precursor in the penicillin biosynthetic pathway.
Mixtures: POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1000 ML, POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1500 MLMidecamycin
go.drugbank.com/drugs/DB13456InvestigationalIn this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar.
Masitinib
go.drugbank.com/drugs/DB11526InvestigationalVet approvedMasitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. It has been available in Europe since 2009, under the brand name Masivet. … In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
Synonyms: 4-((4-METHYLPIPERAZIN-1-YL)METHYL)-N-(4-METHYL-3-((4-PYRIDIN-3-YL-1,3-THIAZOL-2-YL)AMINO)PHENYL)BENZAMIDECilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalCilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigationalTixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Arginine
go.drugbank.com/drugs/DB00125ApprovedInvestigationalNutraceuticalAn essential amino acid that is physiologically active in the L-form.
Mixtures: POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1000 ML, POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1500 MLTepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalIn February 2022, tepotinib was approved for use in Europe.[L42200] … [A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is
Oxolamine
go.drugbank.com/drugs/DB13216ApprovedOxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant [L5416]. It is listed as a prescription drug in New Zealand legislation [L5419]. … Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation [L5422].
Mixtures: ASE-COLD 120 mg+50mg+1mg/5 ml PEDİATRİK ŞURUPProducts: PEREBRON 50MG/5 ML 120 ML SURUPMilbemycin oxime
go.drugbank.com/drugs/DB11531ExperimentalVet approvedMixtures: Nexgard Spectra 150mg/30mg Chewable Tablets for Dogs >30-60kg, Nexgard Spectra 75mg/15mg Chewable Tablets for Dogs >15-30kg